{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:51:44Z","timestamp":1783525904542,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acid Sphingomyelinase Deficiency (ASMD) type B is a rare lysosomal disorder caused by SMPD1 mutations. Due to its low prevalence and clinical heterogeneity, diagnosis is challenging, and detection is crucial for the initiation of enzyme replacement therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study (RnIPH 2024-85) at Toulouse University Hospital, analyzing 359,802 lipid profiles (2012\u20132023). We identified individuals with a total cholesterol\/HDL cholesterol ratio\u2009&gt;\u20094.5. A regex-based extraction method screened records for consanguinity, hepatomegaly, splenomegaly, and ground-glass opacities (GGOs), while we also analyzed thrombocytopenia (&lt;\u2009150\u2009\u00d7\u200910\u2079\/L). Patients meeting\u2009\u2265\u20094\/5 criteria underwent clinical review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 63,653 patients with dyslipidemia, 20.3% had thrombocytopenia, 4.93% hepatosplenomegaly, 2.29% GGOs, and 0.24% consanguinity. In total, 179 patients met\u2009\u2265\u20094\/5 criteria. Nineteen (10.6%) were pediatric. Three previously diagnosed ASMD type B patients in our center were identified. Additionally, among other conditions, 46 cases (25.7%) had monogenic diseases, and five undiagnosed patients were flagged for ASMD screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our hybrid screening effectively identified ASMD type B cases and potential candidates for genetic testing. This approach combining algorithmic filtering and clinical expertise, could enhance ASMD type B diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03746-9","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T09:22:26Z","timestamp":1748251346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advanced strategies for detecting acid sphingomyelinase deficiency type B with attenuated phenotypes"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1947-3401","authenticated-orcid":false,"given":"Thomas","family":"Villeneuve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Jamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Schwob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Levade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Pr\u00e9vot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"3746_CR1","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s10545-007-0632-9","volume":"30","author":"EH Schuchman","year":"2007","unstructured":"Schuchman EH. The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann\u2013Pick disease. J Inherit Metab Dis. 2007;30:654\u201363.","journal-title":"J Inherit Metab Dis"},{"key":"3746_CR2","first-page":"967","volume":"19","author":"MM McGovern","year":"2017","unstructured":"McGovern MM, et al. Consensus recommendation for a diagnostic guideline for acid Sphingomyelinase deficiency. Genet Sci. 2017;19:967\u201374.","journal-title":"Genet Sci"},{"key":"3746_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13023-017-0572-x","volume":"12","author":"MM McGovern","year":"2017","unstructured":"McGovern MM, Avetisyan R, Sanson B-J, Lidove O. Disease manifestations and burden of illness in patients with acid Sphingomyelinase deficiency (ASMD). Orphanet J Rare Dis. 2017;12:41.","journal-title":"Orphanet J Rare Dis"},{"key":"3746_CR4","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13023-021-01842-0","volume":"16","author":"MM McGovern","year":"2021","unstructured":"McGovern MM, et al. Prospective study of the natural history of chronic acid Sphingomyelinase deficiency in children and adults: eleven years of observation. Orphanet J Rare Dis. 2021;16:212.","journal-title":"Orphanet J Rare Dis"},{"key":"3746_CR5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13023-023-02700-x","volume":"18","author":"RH Lachmann","year":"2023","unstructured":"Lachmann RH, et al. Olipudase Alfa enzyme replacement therapy for acid Sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults. Orphanet J Rare Dis. 2023;18:94.","journal-title":"Orphanet J Rare Dis"},{"key":"3746_CR6","first-page":"1543","volume":"23","author":"GA Diaz","year":"2021","unstructured":"Diaz GA, et al. One-year results of a clinical trial of olipudase Alfa enzyme replacement therapy in pediatric patients with acid Sphingomyelinase deficiency. Genet Sci. 2021;23:1543\u201350.","journal-title":"Genet Sci"},{"key":"3746_CR7","doi-asserted-by":"crossref","unstructured":"Mistry PK et al. Acid Sphingomyelinase deficiency and gaucher disease: underdiagnosed and often treatable causes of hepatomegaly, splenomegaly, and low HDL cholesterol in lean individuals. Hepatol Commun 9, (2025).","DOI":"10.1097\/HC9.0000000000000621"},{"key":"3746_CR8","doi-asserted-by":"publisher","first-page":"109081","DOI":"10.1016\/j.ymgme.2025.109081","volume":"145","author":"R Froissart","year":"2025","unstructured":"Froissart R, Pettazzoni M, Pagan C, Levade T, Vanier MT. Acid Sphingomyelinase deficiency: laboratory diagnosis, genetic and epidemiologic aspects of a 50-year French cohort. Mol Genet Metab. 2025;145:109081.","journal-title":"Mol Genet Metab"},{"key":"3746_CR9","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1007\/s12325-023-02453-w","volume":"40","author":"R Pulikottil-Jacob","year":"2023","unstructured":"Pulikottil-Jacob R, Ganz ML, Fournier M. Petruski-Ivleva, N. Healthcare service use patterns among patients with acid Sphingomyelinase deficiency type B: A retrospective US claims analysis. Adv Ther. 2023;40:2234\u201348.","journal-title":"Adv Ther"},{"key":"3746_CR10","doi-asserted-by":"publisher","unstructured":"Noth I et al. Machine learned decision tree for diagnosis of ASMD among patients with unexplained ILD. In rare ILD\/DPLD PA3948 (European respiratory society, 2023). https:\/\/doi.org\/10.1183\/13993003.congress-2023.PA3948","DOI":"10.1183\/13993003.congress-2023.PA3948"}],"updated-by":[{"DOI":"10.1186\/s13023-025-03996-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000}}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03746-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03746-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03746-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:27:36Z","timestamp":1764138456000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03746-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3746"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03746-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13023-025-03996-7","URL":"https:\/\/doi.org\/10.1186\/s13023-025-03996-7","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study, conducted at Toulouse University Hospital (RnIPH 2024-85), is exempt from Ethics Committee submission under French law and complies with MR-004 methodology and GDPR regulations (EU 2016\/679). It is registered with CNIL (2206723 v 0), ensuring full adherence to ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TV, TJ, and RS have nothing to declare. TL declares that over the past four years, consultation agreements have been established through INSERM or CHU Toulouse for a contract providing financial support for investigator-initiated research (Sanofi) and for honoraria received for presentations (Sanofi-Aventis, Chiesi) or consulting (Aceragen); payments were made to INSERM or CHU Toulouse. GP declares that over the past four years, he has received honoraria for presentations as an oral speaker for Sanofi.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"252"}}